Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Chlamydia screening and PID

This article was originally published in The Gray Sheet

Executive Summary

Chlamydia screening and PID: Women screened and treated for asymptomatic chlamydial infectious were 60% less likely than unscreened women to develop pelvic inflammatory disease, University of Washington researcher Delia Scholes, PhD, et al., report in the May 23 New England Journal of Medicine. The study enrolled 2,607 women, ages 18 to 34, in a staff-model HMO and randomly assigned them to either testing for chlamydia or usual care. "At the end of the follow-up period, there had been nine verified cases of pelvic inflammatory disease among the women in the screening group and 33 cases among the women receiving usual care," the researchers write. The study was sponsored by the National Institute of Allergy and Infectious Diseases...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel